{"unnormalised": "AIIMS Delhi announced a breakthrough in targeted cancer therapy. A clinical trial, registered as CTRI/2023/11/058763, showed significant tumor reduction in patients with Stage III lung cancer. The study, published in the Lancet Oncology, involved 150 patients treated with a novel drug, OncoBlock-20, developed in collaboration with ICMR. Dr. Rajesh Kumar, head of oncology, presented the findings at a press conference on 16/11/2024.", "normalised": "A-I-I-M-S Delhi announced a breakthrough in targeted cancer therapy. A clinical trial, registered as C-T-R-I slash two thousand twenty three slash eleven slash zero five eight seven six three, showed significant tumor reduction in patients with Stage three lung cancer. The study, published in the Lancet Oncology, involved one hundred and fifty patients treated with a novel drug, OncoBlock-twenty, developed in collaboration with I-C-M-R. Doctor Rajesh Kumar, head of oncology, presented the findings at a press conference on sixteenth november two thousand and twenty four."}
{"unnormalised": "The results indicated a 60% response rate, with minimal side effects compared to traditional chemotherapy. Patients received OncoBlock-20 at a dosage of 200mg daily for 12 weeks. PET scans revealed an average tumor shrinkage of 4.5 cm in diameter across the cohort. Further research is underway to assess the long-term efficacy and potential applications for other cancer types. The treatment costs approx. Rs. 3 Lakhs per patient.", "normalised": "The results indicated a sixty percent response rate, with minimal side effects compared to traditional chemotherapy. Patients received OncoBlock-twenty at a dosage of two hundred milligram daily for twelve weeks. P-E-T scans revealed an average tumor shrinkage of four point five centimeter in diameter across the cohort. Further research is underway to assess the long-term efficacy and potential applications for other cancer types. The treatment costs approximately rupee three lakhs per patient."}
{"unnormalised": "This advancement is particularly relevant for India, where cancer incidence is rapidly increasing. According to the National Cancer Registry Programme (NCRP), there are an estimated 1.4 million new cancer cases annually. The study highlights the importance of investing in indigenous research to develop affordable and accessible cancer treatments. Experts believe OncoBlock-20 could become a standard-of-care option for lung cancer in the near future.", "normalised": "This advancement is particularly relevant for India, where cancer incidence is rapidly increasing. According to the National Cancer Registry Programme (N-C-R-P), there are an estimated one point four million new cancer cases annually. The study highlights the importance of investing in indigenous research to develop affordable and accessible cancer treatments. Experts believe OncoBlock-twenty could become a standard-of-care option for lung cancer in the near future."}
{"unnormalised": "Several other hospitals, including Tata Memorial Centre in Mumbai and Christian Medical College (CMC) Vellore, are planning to conduct similar trials to validate the findings. Funding for these trials is expected to come from both government agencies and private pharmaceutical companies. The Drug Controller General of India (DCGI) is currently reviewing the data for potential approval.", "normalised": "Several other hospitals, including Tata Memorial Centre in Mumbai and Christian Medical College (C-M-C) Vellore, are planning to conduct similar trials to validate the findings. Funding for these trials is expected to come from both government agencies and private pharmaceutical companies. The Drug Controller General of India (D-C-G-I) is currently reviewing the data for potential approval."}
{"unnormalised": "The team at AIIMS Delhi expressed optimism about the potential of OncoBlock-20 to improve patient outcomes. They emphasized the need for early detection and access to advanced treatment options. A helpline number, 1800-11-2233, has been established to provide information and support to cancer patients and their families. Further details can be found on the AIIMS website, www.aiims.edu.", "normalised": "The team at A-I-I-M-S Delhi expressed optimism about the potential of OncoBlock-twenty to improve patient outcomes. They emphasized the need for early detection and access to advanced treatment options. A helpline number, one eight hundred dash eleven dash two two three three, has been established to provide information and support to cancer patients and their families. Further details can be found on the A-I-I-M-S website, triple w dot a-i-i-m-s dot e-d-u."}
